InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
InMed Pharmaceuticals (NASDAQ: INM) appointed Neil Klompas, CPA, CA to its board effective October 9, 2025.
Klompas brings 30+ years of healthcare and biotech experience, including roles as President and COO and earlier CFO at Zymeworks, where he helped scale the company and led its 2017 IPO. He is currently CEO of Augerex Life Science and serves on the boards of NervGen Pharma and HTuO Biosciences. InMed highlighted Klompas’ operational, financial and capital-markets expertise as supportive for advancing its pipeline; Klompas praised InMed's science and cited INM-901 data as a draw.
InMed Pharmaceuticals (NASDAQ: INM) ha nominato Neil Klompas, CPA, CA al consiglio di amministrazione con effetto dal 9 ottobre 2025.
Klompas porta con sé oltre 30 anni di esperienza nel settore sanitario e biotecnologico, tra ruoli come Presidente e COO e in precedenza CFO presso Zymeworks, dove ha contribuito a far crescere l’azienda e ha guidato il suo IPO 2017. Attualmente è CEO di Augerex Life Science e fa parte dei consigli di NervGen Pharma e HTuO Biosciences. InMed ha evidenziato l’expertise operativa, finanziaria e di mercati dei capitali di Klompas come utile per avanzare la pipeline; Klompas ha elogiato la scienza di InMed e ha citato i dati INM-901 come elemento attrattivo.
InMed Pharmaceuticals (NASDAQ: INM) nombró a Neil Klompas, CPA, CA a su junta directiva con efecto a partir del 9 de octubre de 2025.
Klompas aporta más de 30 años de experiencia en atención sanitaria y biotecnología, incluyendo cargos como Presidente y COO y, anteriormente, CFO en Zymeworks, donde ayudó a escalar la empresa y dirigió su OPI 2017. Actualmente es CEO de Augerex Life Science y forma parte de las juntas de NervGen Pharma y HTuO Biosciences. InMed destacó la experiencia operativa, financiera y de mercados de capital de Klompas como útil para avanzar en su pipeline; Klompas elogió la ciencia de InMed y citó los datos de INM-901 como un atractivo.
InMed Pharmaceuticals (NASDAQ: INM)가 Neil Klompas, CPA, CA를 2025년 10월 9일부로 이사회에 선임했습니다.
Klompas는 30년 이상의 보건의료 및 생명공학 분야 경험을 가지고 있으며, Zymeworks에서 사장 및 COO 등으로 근무하고 이전에는 CFO로 회사를 성장시키고 2017년 IPO를 주도했습니다. 현재 Augerex Life Science의 CEO이며 NervGen Pharma 및 HTuO Biosciences 이사회에도 속해 있습니다. InMed는 Klompas의 운영, 재무 및 자본시장 전문성을 파이프라인 진전에 도움이 되는 요소로 강조했고, Klompas는 InMed의 과학을 높이 평가하며 INM-901 데이터가 매력적이라고 언급했습니다.
InMed Pharmaceuticals (NASDAQ: INM) a nommé Neil Klompas, CPA, CA au conseil d’administration à compter du 9 octobre 2025.
Klompas apporte plus de 30 ans d’expérience dans les soins de santé et la biotechnologie, notamment des postes de Président et COO et, auparavant, CFO chez Zymeworks, où il a aidé à faire croître l’entreprise et a dirigé son IPO 2017. Il est actuellement CEO d’Augerex Life Science et siège au conseil d’administration de NervGen Pharma et HTuO Biosciences. InMed a souligné l’expertise opérationnelle, financière et des marchés de capitaux de Klompas comme favorable à l’avancement de son pipeline; Klompas a loué la science d’InMed et a cité les données INM-901 comme un atout.
InMed Pharmaceuticals (NASDAQ: INM) hat Neil Klompas, CPA, CA mit Wirkung zum 9. Oktober 2025 in den Aufsichtsrat berufen.
Klompas bringt über 30 Jahre Erfahrung im Gesundheitswesen und in der Biotechnologie mit, darunter Positionen als Präsident und COO und zuvor CFO bei Zymeworks, wo er das Unternehmen skalierte und dessen IPO 2017 leitete. Derzeit ist er CEO von Augerex Life Science und gehört den Vorständen von NervGen Pharma und HTuO Biosciences an. InMed hob Klompas’ operative, finanzielle und kapitalmarktorientierte Expertise als hilfreich für die Weiterentwicklung der Pipeline hervor; Klompas lobte die Wissenschaft von InMed und verwies auf die INM-901-Daten als Attraktor.
InMed Pharmaceuticals (NASDAQ: INM) عيّنت نيال كلومبس، CPA، CA في مجلس إدارتها اعتباراً من 9 أكتوبر 2025.
يجلب كلومبس أكثر من 30 عاماً من الخبرة في الرعاية الصحية والتكنولوجيا الحيوية، بما في ذلك مناصب كرئيس ومدير عمليات ومسؤول مالي سابق في Zymeworks، حيث ساعد في توسيع الشركة وقاد طرحها للاكتتاب العام 2017. وهو حالياً الرئيس التنفيذي لـ Augerex Life Science ويشغل مقاعد في مجالس NervGen Pharma و HTuO Biosciences. أكدت InMed أن خبرة كلومبس التشغيلية والمالية وسوق رأس المال ستدعم تقدم خط أنابيبها؛ مدح كلومبس علم InMed وأشار إلى بيانات INM-901 كجاذب.
InMed Pharmaceuticals (NASDAQ: INM) 任命 Neil Klompas, CPA, CA 于 2025 年 10 月 9 日起加入董事会。
Klompas 拥有超过 30 年 的医疗保健与生物科技领域经验，其中包括在 Zymeworks 担任主席兼首席运营官以及此前的 CFO，在那里他帮助公司实现规模化并领导了其 2017 年首次公开募股。他目前任 Augerex Life Science 的 CEO，并在 NervGen Pharma 与 HTuO Biosciences 的董事会任职。InMed 强调 Klompas 在运营、财务与资本市场方面的专长有助于推进其管线；Klompas 赞扬 InMed 的科技，并将 INM-901 的数据视为吸引点。
- Adds 30+ years of healthcare and biotech experience
- Experience as President/COO and former CFO of Zymeworks
- Led Zymeworks' 2017 IPO, bringing capital-markets expertise
- None.
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately.
Mr. Klompas brings over 30 years of experience in healthcare and biotechnology across operational, financial, and R&D functions. He was a key member of the executive leadership team at Zymeworks Inc. (NASDAQ: ZYME) for more than 16 years, where he most recently served as President and Chief Operating Officer, following his tenure as Chief Financial Officer. During his tenure, he was instrumental in helping scale the company from early-stage development into a multi-billion-dollar pharmaceutical company, establishing Zymeworks as a recognized leader in biotherapeutics. Mr. Klompas also led the Company's successful 2017 IPO on the New York Stock Exchange.
Mr. Klompas began his career at KPMG in Canada and the United States, advising on transactions across the pharmaceuticals, biotechnology, and medical devices sectors. He currently holds the position of CEO at Augerex Life Science Corp, serves on the board of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences, and has previously held multiple director and advisory positions in biotechnology, including with Liminal Biotherapeutics and Ovensa Inc.
Mr. Andrew Hull, Chairman of the Board of InMed, commented:
"We are thrilled to welcome Neil to the Board. His broad executive leadership background, financial expertise, extensive capital markets experience, and proven track record in building a successful biotechnology company will be invaluable to InMed as we advance our programs through their next stages of development."
Mr. Neil Klompas commented:
"I'm very excited to be joining the InMed Board, drawn by the strength of its science and the caliber of the team," said Mr. Klompas. "In particular, INM-901 has shown compelling data supporting its multi-pathway approach to treating Alzheimer's disease, and I look forward to contributing my experience as InMed continues to advance its innovative pipeline and strategic growth initiatives."
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: Advancing its programs through their next stages of development; advancing its innovative pipeline and strategic growth initiatives and developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1. of the Annual Report for the period ended June 30, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269794
FAQ
Who was appointed to the InMed board on October 9, 2025 (INM)?
What experience does Neil Klompas bring to InMed (INM)?
Does Neil Klompas hold any current executive or board roles relevant to INM investors?
How might Neil Klompas' appointment affect InMed's strategic direction (INM)?
Did Neil Klompas comment on InMed programs such as INM-901?
Is there any immediate financial guidance or transaction tied to the board appointment for INM?
